Tasquinimod(ABR-215050)
产品编号: DC7733
Featured
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
Tasquinimod是一种口服抗血管生成剂，有潜力用于去势抵抗性前列腺癌的研究。Tasquinimod与 HDAC4 Zn2+ 结合结构域结合的Kd 值为10-30 nM。Tasquinimod 也是一种 S100A9 抑制剂。
| Cas No.: |
254964-60-8 |
| 名称: |
|
| 别名: |
ABR-215050; ABR215050; ABR 215050 |
| SMILES: |
CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O |
| 分子式: |
C20H17F3N2O4 |
| 分子量: |
406.36 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling.Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the an |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
询盘
